Momoko Nishikori

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Recent advances and future perspectives in the treatment of mantle cell lymphoma

Recent advances and future perspectives in the treatment of mantle cell lymphoma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 03, 2026

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

Journal: International journal of hematology

Published: June 25, 2026

Usefulness of pegfilgrastim for allogeneic peripheral blood stem cell collection from healthy donors.

Usefulness of pegfilgrastim for allogeneic peripheral blood stem cell collection from healthy donors.

Journal: Transfusion

Published: March 24, 2026

Prolonged isolated dysgeusia as an initial manifestation of neurolymphomatosis in primary central nervous system lymphoma: illustrative case.

Prolonged isolated dysgeusia as an initial manifestation of neurolymphomatosis in primary central nervous system lymphoma: illustrative case.

Journal: Journal of neurosurgery. Case lessons

Published: March 24, 2026

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Journal: Cancer science

Published: March 05, 2026

Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma.

Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 04, 2026

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Journal: Blood advances

Published: February 04, 2026

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Journal: Blood advances

Published: February 04, 2026

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Journal: Annals of hematology

Published: January 13, 2026

Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

Journal: International journal of hematology

Published: October 04, 2025

Molecular pathogenesis and treatment of follicular lymphoma

Molecular pathogenesis and treatment of follicular lymphoma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.

Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.

Journal: Cytotherapy

Published: September 07, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026